Last week, there were two positive developments relating to Pfizer (NYSE: PFE) and its German partner BioNTech’s Covid-19 vaccine, and one possible negative development. Firstly, Pfizer says based on internal testing that its vaccine can tolerate warmer temperatures than initially specified, possibly making it easier to handle and distribute. Under current protocol, the vaccine is being stored and transported at ultra-cold temperatures of -80 to -60 degrees Celsius until five days before use, calling for specialized equipment and a longer thawing period. However, the company is now asking the FDA to allow the shot to be stored for up to two weeks at -25 to -15 degrees Celsius, enabling the use of more standard freezers. This could make the shot more accessible in rural areas and emerging markets that don’t have special freezers. That said, rival Moderna’s shot is still easier to handle, as it can be stored at standard freezer temperatures for as long as six months and remain
México denunciará ante ONU desigualdad en el acceso a las vacunas
lasillarota.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from lasillarota.com Daily Mail and Mail on Sunday newspapers.
Prometen aceite a precios accesibles , por medio de un fideicomiso agroindustrial
valorlocal.com.ar - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from valorlocal.com.ar Daily Mail and Mail on Sunday newspapers.